

General Information

Name: Prof. Dr. med. Klaus-Michael Debatin
Date of Birth: 06.12.1952
Gender: Male
Address: Department of Pediatrics and Adolescent Medicine, Ulm University, Eythstrasse 24, 89075 Ulm/Germany
Phone: +49 731 500 57001
E-Mail: klaus-michael.debatin@uniklinik-ulm.de
Current Positions: Chairman, Department of Pediatrics and Adolescent Medicine
Deputy Coordinating Investigator, Collaborative Research Center (SFB) 1074 "Experimental models and clinical translation in leukemia"

Academic Education

1971-1978 Medical School, Universities of Ulm, Freiburg and Heidelberg

Academic Degrees

1997 Professor of Pediatrics, Ulm University
1990 Habilitation in Pediatrics, University of Heidelberg
1979 Doctorate degree (Dr. med.), University of Heidelberg

Professional Experience

2015–2024 CEO Centre for Rare Diseases (Zentrum für Seltene Erkrankungen-ZSE), University Medical Center Ulm
2015–2021 Vice President, Ulm University
2013-2015 CEO and Medical Director, Ulm University Hospital
2010-2013 Deputy Medical Director, Ulm University Hospital
2010-2014 Vice President Medicine, Ulm University
2004-2010 Dean, Medical Faculty, Ulm University
2003-2005 Chairman, Science Committee of the Medical Faculty, Ulm University
2002-2004 Vice Dean, Medical Faculty, Ulm University
1995-2002 Head, Division of Molecular Oncology, German Cancer Research Center

1997 Visiting Professor, St. Jude Children's Research Hospital, Memphis
Since 1997 Chairman, Department of Pediatrics, Ulm University
Physician-in-chief of Ulm University Children's Hospital
1994-1997 Head, Hematology/Oncology Section, University Children's Hospital, Heidelberg
1990-1994 Heisenberg Fellow of the German Research Council (DFG)
- National Cancer Institute, USA (Fogarty Fellow)
- German Cancer Research Center, Heidelberg
- Hôpital Necker, Paris
1987-1990 Head of Laboratory of Immunology and Hematology, University Children's Hospital, Heidelberg
1984-1990 Guest scientist, Division of Immunogenetics, German Cancer Research Center, Heidelberg
1983-1990 Clinical fellow and research fellow (Oncology/Immunology Section), University Children's Hospital, Heidelberg
1979-1982 Research fellow (DFG) Institute of Immunology, University of Heidelberg and Max-Planck-Institute for Immunobiology, Freiburg

Miscellaneous

Awards / Honors

2022 CDD Juerg Tschopp Prize (ECDO)
2022 Honorary Doctorate Award Medical Faculty of Duisburg-Essen University
2012 German Cancer Aid Award 2011
2011 Elected Member, European Academy of Cancer Sciences (ECCO)
2011 Career Award, European Cell Death Organisation (ECDO)

2008	ASM Prize 2008 (British Society for Haematology)
2007	Descartes Research Prize 2006 (European Science Fund)
2005	Member of the Heidelberg Academy of Sciences
2002	German Cancer Award
2001	Member of the National Academy of Sciences (Leopoldina)
1998	Wilhelm Warner Award for Cancer Research
1997	SmithKline Beecham Award for Clinical Research
1996	“Presidential Lecture”, International Histiocyte Society
1991	Kind Philipp Award, Society for Pediatric Oncology and Hematology
1990	Heisenberg Fellowship, German Research Council

Positions / Memberships

2013-2020	Member Senate Commission for Clinical Research (SGKF), German Research Council (DFG)
2013-2014	Member, Board of Trustees German Cancer Aid
Since 2012	Member, European Research Institute for Integrated Cellular Pathology (ERI-ICP)
2011-2017	Member, Senate German Research Foundation (DFG)
Since 2010	Member, Steering Committee, Dr. Mildred Scheel Foundation
2009-2015	Member, Advisory Board, Association of German University Hospitals (VUD)
Since 2009	Member, Advisory Board, Dr. Mildred Scheel Foundation (German Cancer Aid)
2009-2015	Member of the Board, German Association of Medical Faculties (MFT)
2005-2007	President ECDO
2004-2010	Member, Scientific Advisory Board, European School of Hematology
2004-2014	Member, Scientific Advisory Board, German Cancer Society (Head since 2009)
2003-2011	Member, Scientific Advisory Board, Interdisciplinary Center for Clinical Research, Jena
Since 2001	Member, Scientific Advisory Board, Children’s Cancer Research Institute, Vienna
2001-2014	Member, Scientific Advisory Board, Georg-Speyer-Haus, Research Institute Frankfurt
Since 2001	Member, Executive Board, German Society for Pediatrics (DGKJ)
2001-2003	Member, Executive Board, Medical Faculty, University of Ulm
1999-2004	Member, Senate Commission Cancer Research, German Research Council (Hinterzartener Kreis)
1999-2002	Program Coordinator, Interdisciplinary Center for Clinical Research Ulm
Since 1997	Member, Steering Committee, Tumor Center Ulm
Since 1994	Member, Executive Committee, European Cell Death Organization (ECDO)
Since 1992	Member, Committee on Biology and Diagnosis IBFM-Study group
1993-1997	Program coordinator, Tumor Center Heidelberg / Mannheim

Publications

1. Trentin L, Queudeville M, Eckhoff S, Hasan M, Münch V, Boldrin E, Seyfried F, Enzenmüller S, Debatin KM*, Meyer LH*. Leukemia reconstitution in vivo is driven by cells in early cell cycle and low metabolic state. **Haematologica**. 2018;103(6):1008-17. *Equal contribution.
2. Münch V, Trentin L, Herzig J, Demir S, Seyfried F, Kraus JM, Kestler H, Köhler R, Barth T, Te Kronnie G, Debatin KM*, Meyer, LH*. Central Nervous System Involvement in Acute Lymphoblastic Leukemia Is Mediated by Vascular Endothelial Growth Factor. **Blood** 2017;130(5):643-654. *Equal contribution.
3. Schirmer M, Trentin L, Queudeville M, Seyfried F, Demir S, Tausch E, Stilgenbauer S, Eckhoff S, Meyer LH*, Debatin KM*. Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. **Cell Death Dis**. 2016;14;7:e2052. *Equal contribution.
4. Loeder S, Schirmer M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, Bertrand MJ, Vandenabeele P, Jeremias I, Debatin KM, Fulda S. RIP1 is required for IAP inhibitor-mediated

sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. **Leukemia**. 2012;26(5):1020-29.

5. Meyer LH, Eckhoff S, Queudeville M, Kraus J, Giordan M, Stursberg J, Zangrando A, Vendramini E, Moricke A, Zimmermann M, Schrauder A, Lahr G, Holzmann K, Schrappe M, Basso G, Stahnke K, Kestler H, Te Kronnie G, Debatin KM. Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. **Cancer Cell**. 2011;19(2):206-17.
6. Meyer LH, Karawajew L, Schrappe E, Ludwig W, Stahnke K, Debatin KM. Cytochrome c related caspase activation determines treatment response and relapse in childhood B-precursor ALL. **Blood**. 2006;107(11):4524-31.
7. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. **Nat Med**. 2002;8(8):808-15.
8. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ ligand system in drug induced apoptosis in leukemia cell. **Nat Med**. 1996;2(5):574-77.
9. Debatin KM, Goldmann CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal antibody-mediated apoptosis in adult T cell leukemia, **Lancet**. 1990;335(8688):497-500.
10. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. **Science**. 1989;245(4915):301-05.